The exact cause of Raynaud's Syndrome is unknown, but we do know a couple of things. We know that patients undergo vasospasm, the thickening of blood vessels, which typically take place in the arteries leading to the limbs and the capillary beds of the toes and fingers (Mayo Clinic Staff, 2015; Zudin et al., 2017). This vasoconstriction is highly correlated to epithelial cell damage, although the cause of this is unknown (Gualtierotti et al., 2017). Limbs are therefore constricted to the amount of oxygenated blood flow they receive and become cold and numb.
It is important to better understand the underlying cause of Raynaud's syndrome because it will aid us in finding new vasoactive therapies and strategies to improve the daily lives of people with the syndrome, especially because there are no cures and few treatments. Take for example my friend Mary, who has been diagnosed with Raynaud's syndrome for a few years now. Her hands and toes will feel numb and painful with simple tasks such as writing notes in class, drinking anything with ice, air conditioner. Sometimes she even feels cold in temperatures up to 90°F. This limits her ability to go outside in the fall and winter unless she bundles up in three to six layers. Sometimes the pain is too much and she cannot take part in regular activities such as building a snowman, going to the pool, or even riding in a cool air conditioned car in the summer. Most patients with Raynaud's experience symptoms like these that become disabling every season of the year (Sandqvist et al., 2017). By applying beneficence to the study of Raynaud's, we can improve the quality of live for patients and one day find a cure.
References:
Cutolo, M., Smith, V., Furst, D., Khanna, D., Herrick, A. (2017). Points to consider
Raynaud's phenomenon in systemic
sclerosis. Rheumatology, Volume 56, Issue
suppl_5, 1 September 2017, Pages v45–v48,
https://doi.org/10.1093/rheumatology/kex199
Gualtierotti, R., Ingegnoli,
F., Griffini, S., Grovetti, E., Borghi, M., Bucciarelli, P.,
Meroni, P.,
Cugno, M. (2017). Detection of early endothelial damage in patients with
Raynaud's phenomenon. Microvascular Research, Volume 113, Issue 1,
pages 22-28, https://doi.org/10.1016/j.mvr.2017.04.004
Mayo Clinic Staff.
(2015). Raynaud's disease. Retrieved
from https://www.mayoclinic.org/diseases-conditions/raynauds
disease/basics/definition/con-20022916
Sandqvist, G., Wollmer, P.,
Scheja, A., Wildt, M., Hesselstrand, R. (2017). Raynaud's
phenomenon
and its impact on activities in daily life during one year of foollow-up in
early systemic sclerosis. Scandinavian Journal of Rheumatology,
Volume 1, Issue 1, pages 1-4 http://dx.doi.org/10.1080/03009742.2017.1350745
Zudin, A., Gristsenko, A.,
Hadzhishvili, I., (2017). The effects of diosmin and
hesperidin on
capillary blood flow of upper limbs in patients with secondary Raynaud's
syndrome. Khirurgiia, Volume 5, Issue 1, pages 60-66.
http://doi.org/10.17116/hirurgia2017560-66.
This is a very interesting syndrome that I have never heard of before! We had learned in class that the process of thermoregulation can be controlled by neural or endocrine mechanisms, so I am wondering if Raynaud's Syndrome is caused by a problem with the neural, endocrine, or both sides of it? I found a review paper by A.L. Herrick from a Rheumatology journal that suggested a combination of defects (neural and endocrine related) as being the cause. Herrick thought that Raynaud's Syndrome may have a decreased threshold for neural receptors responsible for vasoconstriction, which would account for the increased vasoconstriction seen in Raynaud Syndrome patients. This increased vasoconstriction would then lead to epithelial damage, possibly due to oxygen levels not meeting the demands of the epithelial cells. Finally, with the epithelium damaged, they would be unable to release appropriate amounts of vasodilator (decreased NO and prostacyclin) and vasoconstrictor (increased endothelin-1) hormones, continuing the vasoconstriction cycle through a positive feedback loop.
ReplyDeleteWhat I am still a little confused on is what the exact order things are occurring? Herrick's paper was only providing hypotheses to the pathology behind Raynaud's Syndrome, so I completely agree with your statement about more research needing to be conducted to truly understand Raynaud's Syndrome, which would lead to more targeted and better treatment options.
References:
Herrick, A.L. (2005). Pathogenesis of Raynaud's phenomenon. Journal of Rheumatology, 44, 587-596.
doi:10.1093/rheumatology/keh552.
Great post! I’m intrigued by the vasoconstriction correlation to the epithelial cell damage. Perhaps there isn’t enough oxygen and other crucial nutrients being accessed by the epithelia from the underlying connective tissues. It is probably beneficial to look closer at the primary links to this syndrome such as rheumatoid arthritis, Sjörgen’s syndrome, anorexia, and carpal tunnel syndrome. Especially since common symptoms of these are stiffness and joint pain (RA, carpal tunnel, and Sjörgen’s at least). Maybe there is nothing there but that’s something that came to me while reading your post. I also agree with FeiD436, we both talk about possible epithelial damage causes. However, it is possible that one needs to look at the connective tissue to see if there are more overlapping areas, which I started hinting at with the mention of the different maladies Raynaud’s is secondary to.
ReplyDeleteDo you know if your friend feels any amelioration in symptoms if she works out more during colder seasons? I’m sure her doctor has mentioned this to her but I thought it would be interesting to see if that actually helped or not, since exercise promotes blood circulation and delivery of nutrients to affected areas/extremities. Do you also know if she has tried any vasodilator like calcium channel blockers or any hypertensive medications?
One can also tie in Justice to your ethics portion since more than 200,000 patients are afflicted with Raynaud’s every in the US alone. However, I’m sure an obstacle to funding Raynaud’s research is that although it is a common syndrome it is not life threatening and will therefore not be as quickly funded as other more debilitating conditions.
Source: Mayo Clinic